Clinical trials
Recruiting Observational Esophageal Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
89 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2005 | 3 |
| 2006 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 5 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 7 |
| 2023 | 13 |
| 2024 | 12 |
| 2025 | 15 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 89 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fudan University | 5 |
| University Medical Center Groningen | 4 |
| Imperial College London | 3 |
| Sun Yat-sen University | 3 |
| University of Colorado, Denver | 3 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2 |
| M.D. Anderson Cancer Center | 2 |
| Mayo Clinic | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Esophageal Neoplasms | 89 |
| Stomach Neoplasms | 24 |
| Pancreatic Neoplasms | 15 |
| Colorectal Neoplasms | 13 |
| Lung Neoplasms | 13 |
| Liver Neoplasms | 9 |
| Urinary Bladder Neoplasms | 9 |
| Breast Neoplasms | 8 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Prostatic Neoplasms | 8 |
Trials
Showing 1 to 25 of 89. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.